ImmunoScape raises $11M to develop COVID-19 therapies

By The Science Advisory Board staff writers

August 12, 2020 -- ImmunoScape has raised $11 million in financing to research how T-cell immune response contributes to COVID-19 immunity, with the goal of aiding in vaccine and therapy development.

ImmunoScape is collaborating with several vaccine development companies, including the San Diego-based Arcturus, which is running clinical trials in Singapore.

Additionally, ImmunoScape will use the financing to continue enabling advanced immunotherapies for cancer. Anzu Partners led the financing round and was joined by the University of Tokyo Edge Capital in Japan and NPR Holdings in Indonesia.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.